Seeing Is Believing
Currently out of the existing stock ratings of Sumant Kulkarni, 138 are a BUY (86.25%), 22 are a HOLD (13.75%).
Analyst Sumant Kulkarni, currently employed at CANACCORD, carries an average stock price target met ratio of 39.52% that have a potential upside of 29.44% achieved within 174 days.
Sumant Kulkarni’s has documented 317 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on VYGR, Voyager Therapeutics at 13-Mar-2025.
Analyst best performing recommendations are on CRTX (CORTEXYME).
The best stock recommendation documented was for CRTX (CORTEXYME) at 6/3/2019. The price target of $42 was fulfilled within 15 days with a profit of $17.87 (74.06%) receiving and performance score of 49.37.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$20
$2.93 (17.16%)
$20
28 days ago
(07-Mar-2025)
16/21 (76.19%)
$2.39 (13.57%)
172
Buy
$27
$9.93 (58.17%)
$27
1 months 8 days ago
(27-Feb-2025)
7/21 (33.33%)
$7.66 (39.61%)
118
Buy
$28
$10.93 (64.03%)
$28
1 months 8 days ago
(27-Feb-2025)
0/6 (0%)
$8.66 (44.78%)
Buy
$28
$10.93 (64.03%)
$28
1 months 8 days ago
(27-Feb-2025)
25/37 (67.57%)
$8.66 (44.78%)
486
Hold
$22
$4.93 (28.88%)
$24
1 months 24 days ago
(11-Feb-2025)
16/21 (76.19%)
$3.51 (18.98%)
174
Which stock is Sumant Kulkarni is most bullish on?
Which stock is Sumant Kulkarni is most reserved on?
What Year was the first public recommendation made by Sumant Kulkarni?